Exploiting the power of the Fshr reporter, the first comprehensive genetic record of the spatial distribution of FSHR expression offers prospects for extensive exploration of FSH-FSHR biology.

The first-in-class, humanized, epitope-specific FSH-blocking antibody MS-Hu6 is efficacious, durable, and manufacturable, and is therefore poised for further development towards future testing in human trials for osteoporosis, obesity, dyslipidemia and neurodegeneration.

Molecular dynamics simulation of the full-length TSH receptor, a major human autoantigen whose full structure remains uncertain, showed that its linker region is an intrinsically disordered protein, explaining the difficulty of obtaining an experimental structure.

Mathematical and experimental characterization of DUX4 expression dynamics in facioscapulohumeral muscular dystrophy muscle fibers, provides insights into pathology and open-source tools for in silico investigation of anti-DUX4 therapy.

Inhibition of activity in the right frontal eye fields reduces the amplifying effect of gaze in value-based choice.

The most comprehensive neuroanatomical atlas on the expression of three glycoprotein hormone receptors, namely, TSHRs, LHCGRs, and FSHRs, was mapped using RNAscope, a technology that allows the detection of mRNA at single-transcript level.

Intracellular and interorgan skeletal crosstalk highlights integrative skeletal physiology.

Molecular analyses reveal the neuroendocrine control of seasonal life-history transitions in birds.

MS-Hu6 biotherapeutic formulation for the treatment of osteoporosis, obesity, and Alzheimer's disease.

The myopathic transcription factor DUX4 induces discordant dysregulation of transcript and protein levels, demonstrating a key role for post-transcriptional gene regulation in facioscapulohumeral muscular dystrophy.